doxylamine succinate/pyridoxine hydrochloride (Xonvea®)

 

Following a full submission

AWMSG advice

Status: Not recommended

Doxylamine succinate/pyridoxine hydrochloride (Xonvea®) is not recommended for use within NHS Wales for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management. The cost-effectiveness data presented in the submission were insufficient for AWMSG to recommend its use.

 Final Recommendation: doxylamine (Xonvea) 2170 (PDF, 295Kb)
 Appraisal Report: doxylamine (Xonvea) 2170 (PDF, 311Kb)

Medicine details

Medicine name doxylamine succinate/pyridoxine hydrochloride (Xonvea®)
Formulation 10 mg/10 mg film-coated tablet
Reference number 2170
Indication

Treatment of nausea and vomiting of pregnancy in those patients who do not respond to conservative management

Company Alliance Pharmaceuticals Ltd
BNF chapter Central nervous system
Submission type Full
Status Not recommended
Advice number 0819
NMG meeting date 03/04/2019
AWMSG meeting date 15/05/2019
Date of issue 11/06/2019